Skip to main content
Premium Trial:

Request an Annual Quote

Applera to Pay Genetic Technologies $11.2M as Part of Settlement

NEW YORK, Jan. 4 (GenomeWeb News) - A California court has formally dismissed the patent infringement suit between Genetic Technologies and Applera, GTG said today.


As reported by GenomeWeb News on Dec. 12, Applera agreed to settle the lawsuit over GTG's junk DNA gene-testing technologies on Dec. 9.


Under the settlement, Applera agreed to take a license to the GTG non-coding patents and will make payments in the form of cash, equipment, reagents and intellectual property. The payments will total approximately AU$15 million ($11.2 million), GTG said.


The Northern California District Court formally dismissed the lawsuit on Dec. 30.


GTG has favourably resolved six lawsuits involving its patents and does not have any other cases pending.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.